Literature DB >> 12025458

Dilated cardiomyopathies as a cause of congestive heart failure.

Bernhard Maisch1, Arsen D Ristić, Günter Hufnagel, Reinhard Funck, Peter Alter, Daniela Tontsch, Sabine Pankuweit.   

Abstract

DEFINITION AND CLASSIFICATION: Cardiomyopathies are disorders affecting the heart muscle that frequently result in congestive heart failure. Five major forms are recognized: dilated, hypertrophic, restrictive, right ventricular, and nonclassifiable cardiomyopathies with distinct hemodynamic properties. Furthermore, the new WHO/WHF definition also comprises inflammatory cardiomyopathy, defined as myocarditis in association with cardiac dysfunction. Idiopathic, autoimmune, and infectious forms of inflammatory cardiomyopathy were recognized. Viral cardiomyopathy is defined as viral persistence in a dilated heart. It may be accompanied by myocardial inflammation and then termed inflammatory viral cardiomyopathy (or viral myocarditis with cardiomegaly). If no inflammation is observed in the biopsy of a dilated heart (< 14 lymphocytes and macrophages/mm2), the term viral cardiomyopathy or viral persistence in dilated cardiomyopathy should be applied. DIAGNOSIS AND TREATMENT: In recent years, there have been breakthroughs in understanding the molecular and genetic mechanisms involved in this group of conditions, enabling improvement of diagnostic strategies and introduction of new therapies. Ongoing evaluation of antiviral, immunoglobulin, and immunosuppressive therapies including the European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID), removal of antibodies by immunoadsorption, anticytokine and gene therapy, as well as the mechanical support devices may provide new treatment options.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12025458     DOI: 10.1007/s00059-002-2373-8

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  7 in total

1.  Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor.

Authors:  Shusaku Miyata; Genzou Takemura; Yukinori Kawase; Yiwen Li; Hideshi Okada; Rumi Maruyama; Hiroaki Ushikoshi; Masayasu Esaki; Hiromitsu Kanamori; Longhu Li; Yu Misao; Asaki Tezuka; Teruhiko Toyo-Oka; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

3.  Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy.

Authors:  K Komamura; T Sasaki; A Hanatani; J Kim; K Hashimura; Y Ishida; Y Ohkaru; K Asayama; T Tanaka; A Ogai; T Nakatani; S Kitamura; K Kangawa; K Miyatake; M Kitakaze
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

Review 4.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

5.  Preliminary clinical study of left ventricular myocardial strain in patients with non-ischemic dilated cardiomyopathy by three-dimensional speckle tracking imaging.

Authors:  Fengxia Duan; Mingxing Xie; Xinfang Wang; Yuman Li; Lin He; Lan Jiang; Qian Fu
Journal:  Cardiovasc Ultrasound       Date:  2012-03-07       Impact factor: 2.062

Review 6.  A systematic review of intravenous gamma globulin for therapy of acute myocarditis.

Authors:  Joan L Robinson; Lisa Hartling; Ellen Crumley; Ben Vandermeer; Terry P Klassen
Journal:  BMC Cardiovasc Disord       Date:  2005-06-02       Impact factor: 2.298

7.  Intravenous immunoglobulin for presumed viral myocarditis in children and adults.

Authors:  Joan Robinson; Lisa Hartling; Ben Vandermeer; Meghan Sebastianski; Terry P Klassen
Journal:  Cochrane Database Syst Rev       Date:  2020-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.